Arbuckle Stuart A's Form 4 filing
Vertex Pharmaceuticals Inc (VRTX) · filed Feb 21, 2024
- Accession no.
- 0000875320-24-000068
- Filed
- Feb 21, 2024
- Trade date
- Feb 16-20, 2024
- Filing delay
- 5 days
- Rule 10b5-1 plan
- Checked
This filing lists 3 non-derivative transactions. Open-market sales total $2.02M. It was filed 5 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Arbuckle Stuart ACIK 0001557290 | Officer (EVP, COO) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Feb 16, 2024 | Common Stock | FTax withholdingDisposed | −4,499 | $424.01 | −$1,907,620.99 | 71,219 | Direct | |
| Feb 20, 2024 | Common Stock | FTax withholdingDisposed | −3,373 | $420.58 | −$1,418,616.34 | 67,846 | Direct | |
| Feb 20, 2024 | Common Stock | SSaleDisposed | −4,804 | $420.79 | −$2,021,475.16 | 63,042 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.